Insider Buying: Roquefort Therapeutics plc (LON:ROQ) Insider Acquires £12,000 in Stock

Roquefort Therapeutics plc (LON:ROQ) insider Stephen Paul West bought 400,000 shares of the company’s stock in a transaction dated Tuesday, February 4th. The shares were acquired at an average cost of GBX 3 ($0.04) per share, with a total value of £12,000 ($14,923.52).

Roquefort Therapeutics Trading Up 4.1 %

ROQ opened at GBX 2.40 ($0.03) on Friday. The firm has a market capitalization of £3.09 million, a price-to-earnings ratio of -239.50 and a beta of 0.05. The company’s 50 day simple moving average is GBX 3.96 and its two-hundred day simple moving average is GBX 3.98. Roquefort Therapeutics plc has a 1-year low of GBX 2.15 ($0.03) and a 1-year high of GBX 9.50 ($0.12). The company has a debt-to-equity ratio of 12.37, a current ratio of 0.79 and a quick ratio of 3.07.

About Roquefort Therapeutics

Roquefort Therapeutics is a LSE Main Market listed biotech company developing first in class drugs in the high value and high growth oncology segment prior to partnering or selling to big pharma. Since listing in March 2021, Roquefort Therapeutics has successfully acquired Lyramid Pty Limited, a leader in the development of medicines for a new therapeutic target, Midkine (a human growth factor associated with cancer progression), and most recently acquired Oncogeni Ltd, founded by Nobel Laureate Professor Sir Martin Evans, which has developed two families of innovative cell and RNA oncology medicines.